Haplogen has programs discovering and developing antiviral drug candidates. In those programs Haplogen collaborates with professional experts and partners. Typically such a partner contributes know-how in Medicinal Chemistry and preclinical development, whereas Haplogen provides the biological and medical expertise. Our most advanced program is focussed on the development of a drug to prevent rhinovirus caused exacerbations in patients with obstructive lung diseases. This program is expected to apply for first clinical testing in man in 2019.